Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Seckman leaves NPA

This article was originally published in The Tan Sheet

Executive Summary

David Seckman parts ways with the Natural Products Association at the end of July after nine years as executive director to head up the Food Processing Suppliers Association. While with NPA, Seckman "made significant contributions that leave us in an excellent position to continue to meet member needs well into the future," NPA President Debra Short says in a June 11 release. NPA says it will form a search committee to work with a recruitment firm

You may also be interested in...

NPA gets permanent CEO/exec director

The Natural Products Association Oct. 22 names John Gay as its executive director and CEO. NPA President Pat Sardell said Gay's 25 years of working in Washington on policy issues make him "the ideal person for the job." Gay was most recently senior VP of government affairs and public policy for the National Restaurant Association. He also has nonprofit experience and worked as a Senate staffer. Gay will begin the job before the group's Nov. 2 board meeting. Daniel Fabricant, NPA's VP of scientific and regulatory affairs, filled the position on an interim basis after David Seckman departed in July (1"The Tan Sheet" June 15, 2009)

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.

Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning

Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts